LEVELS OF EVIDENCE SCALE

GRADE OF RECOMMENDATIONS
A At least one meta analysis, systematic review, or RCT, or evidence rated as good and directly applicable to the target population B Evidence from well conducted clinical trials, directly applicable to the target population, and demonstrating overall consistency of results; or evidence extrapolated from meta analysis, systematic review, or RCT C Evidence from expert committee reports, or opinions and /or clinical experiences of respected authorities; indicates absence of directly applicable clinical studies of good quality
(Adapted from Scottish Intercollegiate Guidelines Network [SIGN])
iv Apart from surgery, medical therapy, appears to be an attractive treatment option, there being a wide variety of medication available to reduce heavy menstrual bleeding including non-steroidal anti-inflammatory drugs, hormones, anti-fibrinolytics, and intrauterine devices. However, there is considerable variation in practice, and uncertainty, about the most appropriate therapy, due to age, desire to preserve fertility, co-existing medical conditions, and patient preferences (RCOG, 1998; 2001; level 9) .
DEFINITION
Menorrhagia can be defined as a complaint of heavy cyclical menstrual blood loss over several consecutive menstrual cycles in a woman of reproductive years, or more objectively, a total menstrual blood loss of more than 80 ml per menstruation (Hallberg et al, 1966 ).
ASSESSMENT AND INVESTIGATION
Assessment of menstrual blood loss
There is poor correlation between a woman's perception of heavy menstrual bleeding and menstrual blood loss of more than or equal to 80 ml/cycle, and between the amount of sanitary pads used and the complaint of heavy bleeding (Hallberg et al, 1966; Janssen et al, 1995; level 5) .
The gold standard for measuring menstrual bleeding is the alkaline haematin test, which is not freely available in most hospitals in Malaysia, since it is currently considered as an investigative tool for research.
A simpler alternative to this is the pictorial blood loss assessment chart, that does not involve collection of all used sanitary material. It has also been found to correspond well with the alkaline haematin test (Katrina et al, 2001) , and has been validated to be better than the patient's verbal history alone (Higham et al, 1990 ; level 5; Janssen et al, 1995; level 5).
3.2
Pattern of menstrual blood loss It has been noted that while 80-90 % of women with heavy menstrual bleeding have regular cycles, those with prolonged irregular and/or intermenstrual bleeding tend to have other intrauterine pathology (Dijkhuizen et al, 1996; level 5) . On the other hand, for perimenopausal women with delayed menstrual cycles, further investigation is only necessary if blood loss is excessive.
3.3
Pelvic examination An abdominal and pelvic examination to exclude obvious pelvic pathology, is advised in all patients. The Malaysian National Cervical Screening Programme has recommended a cervical smear be taken at the time of the pelvic examination, a pelvic ultrasound be carried out to confirm any abnormal finding, and subsequent referral to a gynaecologist as indicated.
3.4
Full Blood Count Since more than two thirds of women with menstrual blood loss greater than 80 ml per cycle have evidence of anaemia, a low haemoglobin reading is considered an objective indicator of heavy menstrual bleeding. However, a normal haemoglobin reading does not necessarily exclude heavy menstrual bleeding (Hallberg et al, 1966; Janssen et al, 1995; level 5) . Since the signs and symptoms of anaemia do not correlate well with the haemoglobin level until the patient is moderately to severely anaemic, a full blood count would assist in determining the severity of menstrual blood loss.
3.5
Thyroid function test There is no evidence of heavy menstrual bleeding being associated with thyrotoxicosis, but there is some evidence of association in hypothyroid patients (Krassas et al, 1994 ; level 9; Attaran et al 1989). Hence, a routine thyroid function test is not recommended.
3.6
Assessment of endometrium Endometrial pathology in pre-menopausal women with abnormal uterine bleeding is uncommon, with only 20% of cases of endometrial cancer occurring before menopause, mostly in women are aged between 40 -50 years (Crissman et al, 1981 Hunter et al, 1994; level 9) . Infertility and nulli-parity are also significantly associated with hyperplasia. Women who have received tamoxifen appear to be at increased risk of endometrial hyperplasia. However, 14% of the women diagnosed with endometrial hyperplasia had none of the above risk factors.
The Royal College of Obstetricians and Gynaecologists recommends that women with heavy menstrual bleeding but with regular cycles, aged 40 years or less, need not have endometrial samples taken (RCOG, 1994; level 9) . However, some authors suggest that women with irregular bleeding or other risk factors for hyperplasia, should have endometrial sampling irregardless of age (Ash, Farrell & Flowerden, 1996 ; level 9).
The commonly used modes of endometrial assessment are ultrasound scan, endometrial biopsy or aspirate, hysteroscopy and dilatation and curettage (D&C).
Ultrasound
Ultrasonography is a primary diagnostic tool in evaluating women with abnormal vaginal bleeding, being able to demonstrate anatomic findings not frequently detected in pelvic examination. These include small ovarian cysts, leiomyoma, endometrial carcinoma, as well as evaluation of the endometrium with respect to thickness, which would indirectly reflect the endometrial histology, and hormonal status of patients (Okaro, 2003) .
Transvaginal ultrasonography (TVS) is an accurate test for diagnosing endometrial hyperplasia when the endometrial thickness is 12 mm or more (Dijkhuizen et al, 1996 ; level 5; Vercellini et al, 1997; level 5). In women more than 40 years old and who failed medical treatment, 50% have an abnormal TVS (Nagele et al, 1996; level 5)
Hysteroscopy and endometrial biopsy
Hysteroscopy allows for the examination of the whole endometrial cavity, lower segment and cervical canal, being able to detect small polyps or sub-mucous fibroids The main purpose of an endometrial biopsy or aspirate is to exclude endometrial pathology like hyperplasia, endometrial disorders or malignancies. Endometrial biopsy is a simple, quick, safe, and convenient procedure, which can be performed on an ambulatory basis avoiding the need for anesthesia. Furthermore, the device is disposable and is less costly than the conventional D & C.
Routine endometrial biopsy should not be an initial investigation for menorrhagia, being indicated only if menorrhagia persists or in the presence of risk factors (RCOG, 1998, level 9).
Pipelle and Z sampler could be used as the first line endometrial device as they have been found to be more convenient to use compared to the Vabra aspirator (Bunkheila & Powell, 2002) . While the sample adequacy rate was similar for these 3 devices, the Pipelle has been shown to be superior in the detection of atypical hyperplasia and endometrial carcinoma (Dijkhuizen et al, 1996 , level 5).
MANAGEMENT
Medical Treatment
Non Steroidal Anti-Inflammatory Drugs
Endometrial prostaglandins are elevated with excessive menstruation, and he nonsteroidal anti-inflammatory drugs (NSAIDs) reduce prostaglandin levels through the inhibition of the cyclo-oxygenase enzyme with reductions in menstrual blood loss of 25-35% (Irvine &, Cameron, 1999; level 9) . NSAIDs are found to be less effective than tranexamic acid or danazol, but as effective as other medical treatments ( 
Combined oral contraceptive pills
The combined oral contraceptive pill (OCP) in addition to providing contraception causes a 50% reduction in menstrual blood loss by regular shedding of a thinner endometrium nd by inhibiting ovulation (Irvine & Cameron, 1999 , level 9). a
Danazol
Danazol is a synthetic steroid that suppresses oestrogen and progesterone receptors in the endometrium, leading to endometrial atrophy (thinning of the lining of the uterus) and reduced menstrual loss. It is an effective treatment for heavy menstrual bleeding. However, its side-effect profile, its lack of acceptability to women and the need for continuing treatment limits its use ( 
Anti-fibrinolytic agents
Tranexamic acid, a synthetic derivative of the amino acid lysine, exerts an antifibrinolytic effect through reversible blockade on plasminogen, producing a 50% reduction in menstrual loss (Irvine & Cameron, 1999; level 9) . Anti-fibrinolytic therapy causes a greater reduction in objective measurements of heavy menstrual bleeding compared to placebo or other medical therapies ( 
Levonorgestrel intrauterine system
The levonorgestrel intrauterine system (LNG IUS) is a T shaped intrauterine device releasing a steady amount of levonorgestrel (20µg /24 hours) from a steroid reservoir around the vertical stem of the device. It reduces menstrual blood loss by 80% (Irvine & Cameron, 1999; Level 9) , and is found to be more effective than cyclical norethisterone, with patients being more satisfied and willing to continue with treatment. However, these patients experience more side effects such as inter-menstrual bleeding and breast tenderness level 1) . Compared to transcervical resection of the endometrium (TCRE), the LNG IUS produces smaller mean reduction in menstrual blood loss, but there is no difference in the rate of satisfaction with treatment. LNG-IUS appears equally beneficial in improving quality of life and may control bleeding as effectively as conservative surgery over the long term (Marjoribanks, Lethaby, & Farquhar, 2003 ; level 1).
GnRH agonists
Gonadatrophin-releasing hormone (GnRH) agonists induce a reversible hypoestrogenic state, reducing total uterine volume. They are highly effective, but their side-effects make them suitable only for short-term use (Irvine & Cameron, 1999, level 9) .GnRH agonists may obviate emergency surgery in patients with high surgical risk (Vercellini, 1992 ; level 3).
Surgical Management 4.2.1 Medical versus surgical treatment
Medical treatment for menorrhagia is not as effective as surgery despite improvement in control of bleeding. Oral medical therapy is associated with higher incidence of side effects, and approximately 60% of women who had medical treatment would require surgery by 2 years. Surgery has been found to reduce menstrual bleeding more than medical treatment at one year, although the majority of women prefer medical treatment (Marjoribanks, Lethaby & Farquhar, 2003 ; level 1).
Dilatation and curettage
There is little evidence on the effectiveness of dilatation and curettage (D&C) for the relief of menorrhagia. It is not cost effective for the diagnosis of endometrial malignancy in women under 40 years since the prevalence of serious uterine conditions and endometrial cancer is low (Coulter et al, 1993; level 9) . The potential benefits need to be weighed against the risks of anaesthesia and possible complications like uterine perforation and laceration of the cervix (MacKenzie & Bibby, 1978; level 9) . Moreover, a significant proportion of endometrial lesions are not detected by D&C, (Vessey, Clarke, & MacKenzie, 1979) and its usefulness as a diagnostic tool has been repeatedly questioned. D&C may have a diagnostic role when endometrial biopsy is inconclusive and the symptoms persist or when the underlying pathology is suspect.
Endometrial destruction
Endometrial destruction procedures are less invasive, more convenient and less expensive when no other gynecological condition is involved. It enables women to avoid major surgery and results in shorter hospital stay and convalescence. The various energy sources used to destroy the endometrium, are all comparable in terms of efficacy, and the re-operation rate ranges from 0 to 38.2%. The rate is higher in women under the age 35 years in studies where they have been observed for longer duration. The first-generation techniques involve lower costs than a hysterectomy, but the second-generation endometrial destruction techniques involve relatively high purchase and disposable supplies costs. However, these new techniques take less time to perform and have a lower incidence of intra-operative complications. The clinical impact of these two benefits has yet to be demonstrated (AETMIS, 2002; level 1).
Hysterectomy
Hysterectomy is the most widely used treatment, and can be performed abdominally, vaginally or laparoscopically. The vaginal and laparoscopic approaches cause fewer complications and provide a shorter hospital stay and convalescence than abdominal hysterectomy. Although with hysterectomy there is a permanent cessation of menstrual flow resulting in a high level of satisfaction, it is a major invasive procedure incurring morbidity, mortality and costs with a risk of late complications as well. (AETMIS, 2002; level 1). Laparoscopic assisted vaginal hysterectomy is associated with longer operating times, and higher operating costs, but total costs are lower than abdominal hysterectomy. 2. An abdominal and pelvic examination should be performed in women presenting with heavy menstrual bleeding (Grade C).
3. Full blood count should be offered to all women presenting with heavy bleeding (Grade A).
4. Women with heavy menstrual bleeding with severe anemia, should be referred to a specialist for further assessment (Grade C).
5.
Thyroid function test should not be routinely performed in women with heavy menstrual bleeding unless they have signs or symptoms of hypothyroidism (Grade C). 
